IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Influence of Transmission Season on Outcome of Treatment of Schistosoma Haematobium Infection in Mozambique
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention |
|---|---|
| Hematuria Hydronephrosis | Drug: praziquantel |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Influence of Transmission Season on Outcome of Schistosoma Haematobium Infection Treatment Among School Children in Urban and Peri-Urban Areas of Maputo and Matola, Mozambique |
- cure rate
- egg reduction rate
- re-infection prevalence and intensity of infection *resolution of urinary tract pathology
- re-appearance of pathology after re-infection.
- reduction in worm burden (CAA);
| Estimated Enrollment: | 520 |
| Study Start Date: | March 2004 |
| Estimated Study Completion Date: | March 2006 |
General objective To provide knowledge about the influence of transmission season (high and low) on the outcome of treatment assessed by cure rate, re-infection rate, regression and reappearance of urinary tract morbidity rate after treatment in order to optimise praziquantel treatment strategies for morbidity control in urinary schistosomiasis.
Specific objectives To determine the prevalence and intensity of Schistosoma haematobium infection before chemotherapy and compare cure rates and levels of re-infection after chemotherapy administered during high and low transmission seasons.
To assess urinary tract morbidity due to Schistosoma haematobium by ultrasonography and compare the regression and reappearance of urinary tract pathology chemotherapy administered during high and low transmission seasons.
To correlate morbidity determined by ultrasound with infection and morbidity parameters such as intensity of infection, micro- and macrohematuria, circulating cathodic antigen (CCA) in urine, proteinuria and leucocyturia and determine sensitivity, specificity and positive predictive values in relation to urinary tract morbidity.
Study design The main research question concerning the influence of transmission season on treatment outcome will be addressed in a consecutive cohort study with two separate but comparable cohorts. The first cohort will be examined and treated with praziquantel during the season with high transmission, February/Mach (group A) and the second cohort will be examined and treated during the low transmission season, in July approximately 5 months later (group B). Each cohort will be examined before treatment and 2, 6 and 18 months after treatment.
The study will be carried out in 4 primary schools; two from Machava J area and two from Costa do Sol area. The schools will be selected based on the following criteria: similar prevalence (> 50%) and intensity of S. haematobium infection; absence or very low levels of S. mansoni infection; a minimum of 2 classes (>35 pupils per class) at each level (3rd and 4th level) and similar distribution of boys and girls.Examinations will include urine for parasitology and haematuria and ultrasonography of upper and lower urinary tract
Eligibility| Ages Eligible for Study: | 8 Years to 12 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- children aged 8-12 years
Exclusion Criteria:
- All children presenting with macro-haematuria or severe pathology detected by ultrasonography (large masses, pseudo-polyps or hydronephrosis/hydroureter) at the 6 months follow-up examination will be treated with praziquantel and excluded in the data analysis.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00231322
| Mozambique | |
| Matola | |
| Maputo, Maputo Province, Mozambique | |
| Principal Investigator: | Gerito Augusto, Msc | Instituto Nacional de Saúde |
More Information
Additional Information:
| ClinicalTrials.gov Identifier: | NCT00231322 History of Changes |
| Other Study ID Numbers: |
30/CNSB/03/624-03-0021 |
| Study First Received: | September 30, 2005 |
| Last Updated: | April 19, 2007 |
Keywords provided by DBL -Institute for Health Research and Development:
|
Schistosoma haematobium haematuria ultrasonography Uganda Vesical polyps |
Additional relevant MeSH terms:
|
Hydronephrosis Hematuria Schistosomiasis haematobia Kidney Diseases Urologic Diseases Urination Disorders Hemorrhage Pathologic Processes Urinary Tract Infections |
Infection Schistosomiasis Trematode Infections Helminthiasis Parasitic Diseases Praziquantel Anthelmintics Antiparasitic Agents Anti-Infective Agents |
ClinicalTrials.gov processed this record on July 28, 2017